IBIO, INC. Total Contract Liability
IBIO, INC. (IBIO) had Total Contract Liability of $1.80 million as of 2019-06-30, per its 10-K filed 2020-10-13.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2020-10-13
- 2019-06-30: Contract with Customer, Liability $1.80M.
- 2019-03-31: Contract with Customer, Liability $467.00M.
- 2018-12-31: Contract with Customer, Liability $626.00K.
- 2018-09-30: Contract with Customer, Liability $2.90M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2019-06-30 | $1.80M 10-K · filed 2020-10-13 |
| 2019-03-31 | $467.00M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $626.00K 10-Q · filed 2019-02-13 |
| 2018-09-30 | $2.90M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |